Target
Angiopoietin-like protein 4
Description
Anti-Angiopoietin-like protein 4 Antibody, Non-Fucosylated (BioBet-563ZP) is a human monoclonal IgG1k antibody against Angiopoietin-like protein 4. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Hypercholesterolemia
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Angiopoietin-like protein 4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
angiopoietin-like 4
Background
This gene encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. This protein can also act as an apoptosis survival factor for vascular endothelial cells and can prevent metastasis by inhibiting vascular growth and tumor cell invasion. The C-terminal domain may be proteolytically-cleaved from the full-length secreted protein. Decreased expression of this gene has been associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. This gene was previously referred to as ANGPTL2 but has been renamed ANGPTL4.
Alternative Names
ANGPTL4; angiopoietin-like 4; NL2; ARP4; FIAF; HARP; PGAR; HFARP; TGQTL; UNQ171; pp1158; ANGPTL
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with ANGPTL4 include Plasma Triglyceride Level Quantitative Trait Locus and Gastric Antral Vascular Ectasia.
Related Pathways
Its related pathways are Lipoprotein metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
Function
Mediate the inactivation of lipoprotein lipase LPL, thereby regulating the clearance of triglycerides and lipid metabolism in serum. It may also play a role in regulating glucose homeostasis and insulin sensitivity (possibly). Inhibit endothelial cell proliferation, migration and tubule formation, reduce vascular leakage. Through exogenous expression, it can inhibit the adhesion of endothelial cells and extracellular matrix (ECM), inhibit the reorganization of actin cytoskeleton, the formation of actin stress fibers, and the local adhesion of endothelial cells to ECM containing angptl4 (in vitro). Depending on the context, it may be possible to modulate tumor-related angiogenesis (through similarity). [ANGPTL4 n-terminal chain]: mediates the inactivation of lipoprotein lipase LPL, which plays an important role in regulating the clearance of triglycerides and lipid metabolism in serum. Compared with uncleaved protein, it has higher activity in LPL inactivation.
Post-translational modifications
N-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-563ZP
Description
This is a fully human antibody specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3). The human anti-hANGPTL3 antibody are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth.
Antibody Indication
Hypercholesterolemia
